Latest news with #PEGSBoston
Korea Herald
26-05-2025
- Business
- Korea Herald
Samsung Biologics hits W3tr in cumulative orders this year
Samsung Biologics, the biotech arm of Samsung Group, reported Monday that it has surpassed 3 trillion won ($2.2 billion) in cumulative contract orders for 2025, just five months into the year, following a series of major deals with global pharmaceutical firms. According to a regulatory filing, the company recently signed two new contract manufacturing organization, or CMO, deals totaling 440.5 billion won with pharmaceutical companies based in Europe and Asia. These contracts run through December 2030 and December 2033, respectively. Due to non-disclosure agreements, client names and product details were not disclosed. So far in 2025, Samsung Biologics has signed four CMO deals across the US, Europe and Asia. This achievement represents over 60 percent of its total contract value for 2024, reinforcing the company's global competitiveness. The company now counts 17 of the world's top 20 pharmaceutical companies as clients and has accumulated total orders of approximately $18.2 billion since its founding. With the recent launch of its fifth plant in April, adding 180,000 liters of capacity, Samsung Biologics has expanded its total capacity to 784,000 liters, the largest in the world. Samsung Biologics also maintains strong performance in quality control, recording a 99 percent batch success rate last year and securing 356 manufacturing approvals from global regulators as of April 2025. To expand its global presence, the company has actively participated in major industry events including JPMorgan Healthcare Conference, DCAT Week 2025 and PEGS Boston. Samsung Biologics will next join the BIO International Convention held in Boston this June to further strengthen its global partnerships.
Business Wire
09-05-2025
- Business
- Business Wire
Lightcast Announces Limited Commercial Release of Envisia™ Single-Cell Functional Analysis Platform for Antibody Discovery
CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Lightcast Discovery Ltd., a pioneering life science tools company, today announced the limited commercial release of its Envisia™ benchtop platform — a breakthrough droplet-based, single-cell functional analysis system designed to accelerate antibody discovery and development. The company will debut the instrument at booth #711 and present new data from its technology access program at the Essential Protein and Antibody Engineering Summit (PEGS), taking place May 12-16, 2025, in Boston. 'The Lightcast Envisia platform is truly one of a kind, enabling us to analyze single-cell functional activity in real time,' said Toon Swings, PhD, Technology Expert at VIB. 'The Lightcast Envisia platform is truly one of a kind, enabling us to analyze single-cell functional activity in real time,' said Toon Swings, PhD, Technology Expert at VIB. 'We are able to track cell behavior, administer treatments, and monitor responses over time, which helps identify and select cells of interest for downstream studies.' While traditional single-cell analysis techniques often rely on genomic data to infer function, the Envisia platform uses droplet microfluidics to perform highly controlled, sequential single-cell functional assays that capture rich functional data sets to improve decision making. Built around Lightcast's proprietary light-controlled droplet manipulation technology, the platform enables parallel interrogation of tens of thousands of picoliter-scale droplets, offering unmatched precision and flexibility. By integrating functional screening early in the antibody discovery process, the Envisia platform allows researchers to select and advance the most promising candidates. It also opens new possibilities in cell-cell interaction studies and broader applications in immunology and oncology. 'The Lightcast team is excited to introduce Envisia to the scientific community at PEGS Boston and to highlight the cutting-edge work being done by our pharmaceutical and academic collaborators,' said Paul Loeffen, PhD, CEO of Lightcast. 'This limited product release marks a major milestone as we shift from technology development to customer-driven deployment. Researchers can secure their place now to gain a first-mover advantage and access to unprecedented functional insights that will power the next wave of innovative biologics and therapies.' Featured PEGS Boston Presentations Advances in Immunotherapy Luncheon 'Advancing Antibody Discovery with Single-Cell, Function-Focused Profiling' Presenters: Paul Loeffen, PhD, CEO of Lightcast Kathrin Herbst, PhD, Director of Science at Lightcast Poster Number: A60 Poster Presenter: Simon Margerison Date/Time: May 12-13, 2025 As part of the limited release, Lightcast is working closely with leading pharmaceutical and academic institutions to validate performance, optimize protocols, and expand application areas, all in preparation for the launch of a diverse array of validated protocols later in 2025. The complete Envisia workflow will include advanced instrumentation, intelligent software, a purpose-built cartridge system, and assay kits optimized to a broad array of functional applications. The fully automated, end-to-end workflows will support a wide range of cell types, assay formats, and research applications. To learn more about the Envisia platform, visit About Lightcast Lightcast Discovery aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit Lightcast, the Lightcast logo, and Envisia are trademarks of Lightcast Discovery Ltd.
